Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: A double-blind, crossover, randomised, controlled trial

20Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: To evaluate the proteinuria-lowering effect of a renin inhibitor (aliskiren), compared to placebo and to an angiotensin-converting enzyme inhibitor (perindopril), in patients with non-diabetic chronic kidney disease. Methods: A randomised, double-blind, crossover trial was performed in 14 patients with nondiabetic chronic kidney disease with 24-h mean proteinuria of 2.01 g (95% CI, 1.36-2.66) and estimated creatinine clearance of 93 ± 6.8 ml/min. The study consisted of five treatment periods. The patients were randomly assigned to receive aliskiren (150 mg), aliskiren (300 mg), perindopril (5 mg), perindopril (10 mg) or placebo. Results: Aliskiren and perindopril reduced proteinuria. These effects were dose-dependent. Furthermore, 24-h proteinuria was reduced by 23% (mean 95% CI; 2-44) by treatment with aliskiren (150 mg), by 36% (95% CI, 17-55; P < 0.001) with aliskiren (300 mg), by 7.1% (95% CI, 11-26) with perindopril (5 mg) and by 25% (95% CI, 11-39; P < 0.05) with perindopril (10 mg), compared to placebo. No significant difference was found between the effects of aliskiren and perindopril. Conclusions: Aliskiren significantly reduced proteinuria. The antiproteinuric effect is probably similar to that of perindopril, for equivalent hypotensive dosages. The renin inhibitor provides a promising alternative approach for the treatment of patients with chronic proteinuric non-diabetic kidney disease. © 2012 The Author(s).

References Powered by Scopus

Procedures for Detecting Outlying Observations in Samples

3071Citations
N/AReaders
Get full text

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1804Citations
N/AReaders
Get full text

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency

1760Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Fiend and friend in the renin angiotensin system: An insight on acute kidney injury

68Citations
N/AReaders
Get full text

Aliskiren inhibits renin-mediated complement activation

57Citations
N/AReaders
Get full text

Renin-angiotensin-aldosterone system blockade for nephroprotection: Current evidence and future directions

49Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lizakowski, S., Tylicki, L., Renke, M., Rutkowski, P., Heleniak, Z., Sławińska-Morawska, M., … Rutkowski, B. (2012). Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: A double-blind, crossover, randomised, controlled trial. International Urology and Nephrology, 44(6), 1763–1770. https://doi.org/10.1007/s11255-011-0110-z

Readers over time

‘13‘14‘15‘16‘17‘18‘20‘21‘22‘2302468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

36%

Professor / Associate Prof. 4

29%

Researcher 3

21%

Lecturer / Post doc 2

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

73%

Chemistry 2

13%

Computer Science 1

7%

Nursing and Health Professions 1

7%

Save time finding and organizing research with Mendeley

Sign up for free
0